AltaRex Corp.

Aug 25, 03
09:44 ET	AltaRex Announces Financial Results for Second Quarter 2003
Aug 11, 03
09:39 ET	Extension of License Agreement to United Therapeutics Corporation
Jun 17, 03
09:27 ET	AltaRex Corp. Comes to a Resolution in Lawsuit With ICN Pharmaceuticals Inc.
Jun 02, 03
09:07 ET	OvaRex(R) Study Demonstrates Clinical Benefit for Ovarian Cancer Patients
May 30, 03
15:36 ET	AltaRex Announces Financial Results for First Quarter 2003 and Closure of Boston-area Offices
May 15, 03
08:48 ET	AltaRex Announces Restructuring and Management Changes
07:47 ET	SU: PER -- WITH LOGO -- TO BUSINESS AND MEDICAL EDITORS:
May 05, 03
11:27 ET	OvaRex(R) Update: AltaRex Reports on Rescheduled AACR Presentations
Apr 09, 03
12:40 ET	AltaRex Announces Financial Results for Fourth Quarter and Year Ended December 31, 2002
Mar 03, 03
08:03 ET	AltaRex Presents Key OvaRex(R) Laboratory Data at Keystone Symposium
Feb 03, 03
06:00 ET	AltaRex Phase II OvaRex(R) Survival Data Presented at Society for Gynecological Oncology
Jan 23, 03
12:43 ET	AltaRex Announces OvaRex(R) Clinical Trial and Registration Program
Nov 22, 02
11:54 ET	AltaRex Announces Financial Results for Third Quarter 2002
08:59 ET	AltaRex Updates OvaRex(R) Clinical Program at EORTC Meeting in Frankfurt
Nov 07, 02
09:41 ET	OvaRex(R) Enhanced T Cell Killing Data Presented at SBT
Oct 23, 02
11:01 ET	Webcast for Mass Opportunities Investor Conference
Oct 17, 02
15:41 ET	AltaRex to Present at Healthcare Conferences -- Webcast Alert
Aug 29, 02
08:13 ET	AltaRex Announces Financial Results for Second Quarter 2002
Aug 15, 02
19:41 ET	AltaRex Announces Additional U.S. $2.5 Million Investment By United Therapeutics Under Existing Collaboration
Aug 09, 02
08:47 ET	AltaRex Announces Auditor Change
Aug 02, 02
08:27 ET	AltaRex Receives OvaRex(R) Orphan Drug Designation in Europe
Jul 19, 02
16:06 ET	AltaRex Announces Resignation of Chairman and Chief Scientific Officer
Jul 09, 02
13:32 ET	AltaRex Receives Positive European Opinion for OvaRex(R) as Orphan Drug
Jun 27, 02
10:05 ET	AltaRex To Present OvaRex(R) Mechanistic and Clinical Summary at International Conference
Jun 21, 02
08:31 ET	AltaRex Outlines Strategic Direction at Annual General Meeting of Shareholders
Jun 18, 02
11:02 ET	AltaRex Evaluating New Auditors
Jun 07, 02
08:30 ET	AltaRex Receives OvaRex(R) Notice of Intent to Grant Patent from European Patent Office
May 28, 02
13:03 ET	AltaRex Announces Financial Results for First Quarter 2002
May 21, 02
08:30 ET	AltaRex Presents OvaRex(R) Clinical Studies at ASCO
May 01, 02
15:06 ET	AltaRex Announces Management Changes
Apr 26, 02
16:54 ET	AltaRex Announces Suit by ICN
Apr 22, 02
09:02 ET	AltaRex Presents New Data Supporting Technology Platform at American Association of Immunology Sponsored Conference
Apr 17, 02
23:32 ET	AltaRex and United Therapeutics Sign Exclusive License Agreement
Apr 05, 02
11:09 ET	AltaRex Presents OvaRex(R) Data at AACR Conference
Mar 28, 02
08:28 ET	AltaRex Provides Update of Financing Status
Mar 18, 02
09:48 ET	AltaRex Announces Positive OvaRex(R)-Chemotherapy Trial Results at SGO
Mar 15, 02
11:33 ET	AltaRex Presents Expanded OvaRex(R) Clinical Results at SGO
Mar 07, 02
12:14 ET	AltaRex Announces Private Placement of Special Warrants for up to $7 Million
Mar 05, 02
14:26 ET	AltaRex Initiates OvaRex(R) Pharmacokinetics Study
Feb 26, 02
09:20 ET	AltaRex Announces Financial Results for Fourth Quarter and Full Year 2001
Feb 06, 02
09:05 ET	New OvaRex(R) Phase IIb Clinical Results Statistically Significant Based on Predefined Analysis Plan
Jan 31, 02
13:59 ET	AltaRex Announces Additional Phase IIb Results Indicating OvaRex(R) Improves Time to Relapse in Platinum Sensitive Patients
Jan 24, 02
16:07 ET	AltaRex Announces Positive OvaRex(R) Phase IIb Results
Jan 09, 02
08:31 ET	AltaRex Achieves Major Manufacturing Milestone for OvaRex(R) MAb
Dec 07, 01
12:01 ET	AltaRex Prostate Cancer Antibody Data Presented at AACR Special Conference
Nov 26, 01
07:15 ET	AltaRex Clears Final Prospectus for Exercise of Special Units
Nov 08, 01
07:32 ET	OvaRex(R) Clinical Data Presented by Dr. Jonathan Berek At Chemotherapy Foundation Symposium
Nov 01, 01
08:29 ET	AltaRex Announces Financial Results for Third Quarter 2001
Oct 31, 01
07:31 ET	AltaRex Announces Closing of C$12.6 million Private Placement
Oct 24, 01
08:29 ET	AltaRex to Present OvaRex(R) MAb in Europe at ECCO 11 Meeting
Oct 23, 01
11:42 ET	AltaRex Announces C$12.6 Million Private Placement of Special Units
07:00 ET	AltaRex Presents Foreign Antibody Approach and OvaRex(R) Clinical Data at Engineered Antibodies Conference
Oct 11, 01
08:29 ET	AltaRex Announces Favorable Early OvaRex(R)/Chemo Clinical Trial Results
Oct 04, 01
07:59 ET	AltaRex Corp. to Present at UBS Warburg Global Life Sciences Conference
Sep 04, 01
07:30 ET	AltaRex Completes Pivotal OvaRex(R) Clinical Trial for Primary Analysis
Aug 16, 01
07:30 ET	AltaRex Announces Financial Results for Second Quarter 2001
Jul 30, 01
08:51 ET	AltaRex Announces Exercise of Special Warrants
Jul 27, 01
07:15 ET	AltaRex Reports OvaRex(R) Primary Analysis Results from Placebo-Controlled Trial
Jul 12, 01
08:29 ET	AltaRex Reports Positive OvaRex(R) Long-Term Survival and Safety Results
Jul 10, 01
08:31 ET	AltaRex Publishes OvaRex(R) Clinical and Laboratory Data Demonstrating Novel Mechanism
Jun 22, 01
08:33 ET	AltaRex Appoints Dr. Hans Wigzell to Scientific Advisory Board
08:33 ET	AltaRex to Present Update at BIO 2001
Jun 06, 01
12:52 ET	AltaRex Announces Closing of $8.4 Million Private Placement
09:31 ET	AltaRex Announces Cancer Collaboration with Epigen
May 31, 01
08:15 ET	AltaRex Appoints Jacques R. Lapointe to its Board of Directors
May 25, 01
13:18 ET	AltaRex Announces C$8.4 Million Private Placement of Special Warrants
08:29 ET	AltaRex Elects Bruce D. Brydon To Its Board Of Directors
May 24, 01
08:29 ET	AltaRex Announces Financial Results for the First Quarter 2001
May 14, 01
13:19 ET	AltaRex Releases Preliminary OvaRex(R) Clinical Data from Completed Phase II Trial
May 12, 01
12:30 ET	AltaRex Presents Interim Results of OvaRex(R) Lead Clinical Trial at ASCO
May 10, 01
08:29 ET	AltaRex Licenses U.S. Issued Patents for Autoimmune Disease Therapy
May 07, 01
08:29 ET	AltaRex Presents Positive BrevaRex(R) MAb Results at International Myeloma Workshop
Apr 13, 01
08:29 ET	AltaRex Appoints Two New U.S. Board Members - William R. Darrow and Robert H. Uhl -
Mar 26, 01
09:01 ET	AltaRex Presents Further T cell Response Data at AACR
Mar 21, 01
09:26 ET	AltaRex Presents Important OvaRex(R) Clinical Results
Mar 14, 01
09:11 ET	AltaRex Announces Financial Results for the Fourth Quarter 2000
Mar 13, 01
08:31 ET	AltaRex Announces Positive ProstaRex(TM) Preclinical Data At Keystone Symposium
Mar 06, 01
10:57 ET	Results of OvaRex(R) MAb Study Demonstrate Efficacy and Safety
Feb 13, 01
09:23 ET	AltaRex Announces C$8.3 Million Sale of Common Shares
Feb 09, 01
08:55 ET	AltaRex Appoints Dr. Howard J. Fingert as VP Clinical Operations, Engages CA 125 Co-inventor and Prominent Oncologist Dr. Robert C. Knapp
Feb 08, 01
08:31 ET	AltaRex Technology Platform Extended to Infectious Disease
Jan 26, 01
12:42 ET	AltaRex Announces Up to C$12 Million Common Share Offering
12:31 ET	AltaRex Engages The Trout Group for U.S. Investor Relations
Jan 15, 01
10:22 ET	AltaRex Selects Abbott Laboratories for OvaRex(R) Manufacturing
Jan 08, 01
08:07 ET	AltaRex Receives U.S. OvaRex(R) 'Multi-epitopic' Patent Allowance
Jan 03, 01
08:30 ET	AltaRex Reports Favorable OvaRex(R) Phase II Trial Results
Dec 22, 00
11:18 ET	AltaRex and Dompe Farmaceutici Close on Private Placement
Dec 21, 00
08:31 ET	AltaRex Announces BrevaRex(R) MAb Data Relevant to Multiple Myeloma - Plans Phase I/II Clinical Trial with Leading Center -
Dec 20, 00
08:31 ET	AltaRex Enlists US Oncology Sites for Latest OvaRex(R) MAb Study
Dec 04, 00
14:29 ET	AltaRex Presents Final BrevaRex(R) Phase I Trial Results at ASH Conference
Nov 22, 00
11:52 ET	AltaRex Announces Effective Date of Share Consolidation
Nov 21, 00
08:29 ET	AltaRex Corp. Invites You to Join Its Third Quarter Conference Call on the Web
Nov 20, 00
08:29 ET	AltaRex Corp. Invites You to Join Its Third Quarter Conference Call on the Web
Nov 16, 00
11:14 ET	AltaRex and Dompe Form Strategic Business Alliance
Nov 13, 00
10:31 ET	AltaRex Announces Financial Results for the Third Quarter
Nov 01, 00
09:25 ET	AltaRex to Implement 1 for 4 Share Consolidation
Oct 24, 00
07:53 ET	AltaRex Reports New OvaRex(TM) Clinical Data
07:51 ET	AltaRex Highlights Additional BrevaRex(TM) Phase I Data
Oct 03, 00
09:05 ET	AltaRex Presents New Findings at Cancer Vaccine 2000
Aug 31, 00
08:56 ET	AltaRex Announces Closing of C$1.2 Million Over-Allotment Option
Aug 18, 00
07:59 ET	AltaRex Announces Financial Results and Highlights for the Second Quarter
Aug 09, 00
09:01 ET	AltaRex Announces Closing of C$7.8 Million Common Share Offering
Jul 13, 00
09:32 ET	AltaRex Appoints VP Manufacturing and Director Investor Relations - US Patent Office Issues OvaRex(TM) Patent -
Jul 10, 00
12:35 ET	AltaRex Initiates Joint Venture for Israel and the Middle East
Jun 28, 00
14:55 ET	AltaRex Initiates Joint Venture for Greece and the Balkans
11:13 ET	AltaRex Presents New OvaRex(TM) Data at Antibody Conference
May 22, 00
06:59 ET	OvaRex(TM) Induces Immune Responses Leading to Long-Term Survival
May 12, 00
05:59 ET	AltaRex to Present New OvaRex(TM) Data Fundamental to Tumor Killing
May 11, 00
13:56 ET	AltaRex Corp. Invites You to Join a Conference Call Updating Company Activities
May 05, 00
08:45 ET	AltaRex Announces First Quarter Financial Results and Accomplishments
May 04, 00
09:59 ET	AltaRex Presents The Challenge of Ovarian Cancer: New Therapeutic Strategies
May 03, 00
08:41 ET	OvaRex(TM) Registration and Financing Plans Outlined at AltaRex Annual Meeting
Apr 12, 00
09:41 ET	AltaRex Awarded First U.S. Patent Allowance
09:38 ET	/C O R R E C T I O N -- AltaRex Corp./
Apr 06, 00
09:43 ET	AltaRex Awarded Key Foreign Patent for AIT(R) Cancer Technology
Apr 03, 00
07:00 ET	AltaRex Presents Anti-Tumor Data with Four AIT(R) Antibodies at AACR
Mar 29, 00
10:31 ET	AltaRex Presents OvaRex(TM) MAb Clinical Plan at BIO 2000 Annual Meeting
Mar 20, 00
09:46 ET	AltaRex Announces Successful Completion of BrevaRex(TM) MAb Phase I Study
Mar 09, 00
14:22 ET	AltaRex Announces Exercise of Compensation Options
Mar 07, 00
09:13 ET	AltaRex Reports on OvaRex(TM) MAb Clinical Evidence of Cellular Immune Induction
Feb 29, 00
14:39 ET	AltaRex Announces Closing of Private Placement
Feb 18, 00
09:09 ET	AltaRex Announces Financing and Fourth Quarter Results
Feb 10, 00
09:22 ET	AltaRex Reports on SGO Presentation
Feb 08, 00
08:29 ET	OvaRex(TM) Clinical Data Presented at the Society of Gynecologic Oncologists Annual Meeting
Jan 12, 00
09:06 ET	AltaRex In-Licenses Additional Antibody for AIT(R) Portfolio, Adds Leading Cancer Researchers to Scientific Advisory Board
Dec 07, 99
14:24 ET	AltaRex Publishes Early Prospective OvaRex(TM) MAb Data in the Journal Blood And Announces Updated Results
Nov 18, 99
08:31 ET	AltaRex Announces Financial Results for the Third Quarter Ended September 30, 1999
Oct 22, 99
11:29 ET	AltaRex Announces Operational Changes to Focus Support On Bringing OvaRex(TM) MAb to Market
Oct 14, 99
18:03 ET	AltaRex Announces New Partnering Plans for OvaRex(TM) MAb : Purdue Foregoes Option
Sep 03, 99
11:00 ET	AltaRex and Biomira Announce Settlement of Lawsuits
Aug 12, 99
08:32 ET	AltaRex Announces Financial Results for the Second Quarter Ended June 30, 1999
Jul 13, 99
08:30 ET	AltaRex Announces OvaRex(TM) MAb Clinical Progress
Jun 02, 99
10:00 ET	AltaRex Appoints Marlene R. Booth as Vice President, Regulatory Affairs and Project Management
Jun 01, 99
14:12 ET	AltaRex Announces Closing of Additional C$5.3 Million Under Its Equity Financing
May 26, 99
08:29 ET	AltaRex Announces Financial Results for the First Quarter Ended March 31, 1999
Apr 27, 99
15:14 ET	AltaRex Files Final Prospectus for Financing of Up to C$17 Million
Apr 14, 99
11:01 ET	AltaRex Update - Legal Proceedings With Biomira
Mar 19, 99
07:59 ET	AltaRex Updates Clinical Progress for OvaRex(TM) MAb and BrevaRex(TM) MAb
Mar 17, 99
07:59 ET	AltaRex Files Lawsuit Against Biomira Inc.
Mar 10, 99
12:45 ET	AltaRex Announces Financial Results for the Fourth Quarter and Year Ended December 31, 1998
Mar 02, 99
13:44 ET	AltaRex Announces Commencement of Legal Action By Biomira
Feb 24, 99
10:27 ET	AltaRex Announces Potential Legal Action
Jan 06, 99
11:20 ET	AltaRex Appoints Christopher F. Nicodemus, M.D. as Senior Vice President, Medical and Regulatory Affairs
Nov 17, 98
12:18 ET	AltaRex Announces Financial Results for the Third Quarter Ended September 30, 1998
Nov 05, 98
13:33 ET	AltaRex Submits IND Amendment To Initiate Phase II Trial of OvaRex(TM) MAb For Ovarian Cancer
Oct 13, 98
06:59 ET	AltaRex Submits IND for Second Antibody-Based Product For the Treatment of Cancer
Sep 22, 98
16:01 ET	AltaRex Appoints Edward M. Fitzgerald As Chief Financial Officer
Aug 19, 98
09:36 ET	AltaRex Announces Financial Results for the Second Quarter Ended June 30, 1998
Jul 09, 98
16:11 ET	AltaRex Initiates Second Phase II Study of OvaRex(TM) for Treatment of Ovarian Cancer
Jun 30, 98
16:02 ET	AltaRex Establishes Clinical Advisory Board
May 28, 98
13:52 ET	AltaRex Appoints New Board Members And Announces Management Changes
May 21, 98
13:51 ET	AltaRex Announces Financial Results for the First Quarter Ended March 31, 1998
Apr 29, 98
13:49 ET	AltaRex to Focus on AIT(TM) Immunotherapy Products And Technology And Announces Key Efforts And Milestones For The Next 12-18 Months
Apr 01, 98
13:47 ET	AltaRex Presents Data Supporting Its Breast Cancer Immunotherapeutic, Brevarex(TM), At The American Association For Cancer Research Meeting
Mar 04, 98
08:30 ET	AltaRex Announces Financial Results for the Fourth Quarter and Year Ending December 31, 1997
Feb 25, 98
14:03 ET	AltaRex Welcomes Richard E. Bagley as New President & CEO
Feb 02, 98
13:42 ET	AltaRex Appoints Georges Hibon To Board Of Directors